Exxel Pharma Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference

by jtcir-auto | Feb 19, 2025 | Press Releases

On-demand video webcast now available here AURORA, CO / ACCESS Newswire / February 19, 2025 / Exxel Pharma (“Exxel” or the “Company”), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal...

Exxel Pharma’s Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough

by jtcir-auto | Feb 3, 2025 | Press Releases

Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in normal volunteers expected to commence enrollment in Q3/4 2025 with...

Exxel Pharma to Participate in a “New to Virtual Investor” Segment

by jtcir-auto | Jan 31, 2025 | Press Releases

Live moderated video webcast on Wednesday, February 5th at 4:00 PM ET AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma (“Exxel” or the “Company”), a pharmaceutical company dedicated to developing novel therapeutics for the...

Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity

by jtcir-auto | May 1, 2024 | Press Releases

Live webcast with Soren Mogelsvang, PhD, Chief Executive Officer of Exxel Pharma, on Wednesday, May 8th at 12 PM ETAURORA, CO / ACCESSWIRE / May 1, 2024 / Exxel Pharma (“Exxel” or the “Company”), an early-stage pharma company working to develop...

Exxel Pharma Provides Business Overview and Upcoming Milestones

by jtcir-auto | Jan 25, 2024 | Press Releases

Company advancing innovative, small molecule for treatment of refractory chronic cough where there are currently no FDA-approved therapies Lead program, EX937, initially targeting a $11B global market with potential to expand into multiple high-value indications...